Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus
© 2023 The Authors. Clinical Physiology and Functional Imaging published by John Wiley & Sons Ltd on behalf of Scandinavian Society of Clinical Physiology and Nuclear Medicine..
BACKGROUND: SGLT2 inhibitors have been shown to reduce hospitalisation in patients with chronic heart failure (CHF). The cardioprotective mechanisms of gliflozins however have not been fully elucidated. The aim of this study was therefore to evaluate the effect of SGLT2 inhibitors on right and left ventricular function in patients with diabetes and HF.
METHODS: Seventy-eight patients with diabetes and CHF were enroled in the study and followed up; 38 started treatment with SGLT2i, while the remaining 40 continued their previous antidiabetic therapy. All patients underwent conventional, TDI and strain echocardiography in an ambulatory setting, at the beginning and after 3 months of therapy with SGLT2i.
RESULTS: After 3 months of therapy with SGLT2i, echocardiographic parameters assessing both left and right ventricular dimensions and function were found as significantly improved in patients switching to SGLT2i than control group: LVEF (45 ± 9% vs. 40 ± 8%, p < 0.001), LVEDD (54 ± 6.5 vs. 56 ± 6.5 mm, p < 0.01), GLS (-13 ± 4% vs. -10 ± 3%, p < 0.001), TAPSE (21 ± 3 vs. 19 ± 3 mm, p < 0.001), RV S' (12.9 ± 2.5 vs 11.0 ± 1.9 cm/sec, p < 0.001) and PAsP (24 ± 8 vs. 31 ± 9 mmHg, p < 0.001). Also mitral (1.0 ± 0.5 vs. 1.3 ± 0.5, p < 0.01) and tricuspid regurgitation (1.0 ± 0.5 vs. 1.3 ± 0.5, p < 0.01) improved after SGLT2i therapy. Changes were not statistically significant in patients not treated with SGLT2i (p n.s. in all cases).
CONCLUSIONS: In a real-world scenario, treatment with SGLT2i in patients with CHF and diabetes is associated with an improvement in both left and right ventricular function assessed at echocardiography. These data may explain potential anti-remodelling effects of gliflozins.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Clinical physiology and functional imaging - 44(2023), 1 vom: 05. Jan., Seite 112-117 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Correale, Michele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diabetes |
|---|
| Anmerkungen: |
Date Completed 07.12.2023 Date Revised 07.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cpf.12857 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362893489 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362893489 | ||
| 003 | DE-627 | ||
| 005 | 20231226092207.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cpf.12857 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362893489 | ||
| 035 | |a (NLM)37795627 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Correale, Michele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2023 | ||
| 500 | |a Date Revised 07.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Clinical Physiology and Functional Imaging published by John Wiley & Sons Ltd on behalf of Scandinavian Society of Clinical Physiology and Nuclear Medicine. | ||
| 520 | |a BACKGROUND: SGLT2 inhibitors have been shown to reduce hospitalisation in patients with chronic heart failure (CHF). The cardioprotective mechanisms of gliflozins however have not been fully elucidated. The aim of this study was therefore to evaluate the effect of SGLT2 inhibitors on right and left ventricular function in patients with diabetes and HF | ||
| 520 | |a METHODS: Seventy-eight patients with diabetes and CHF were enroled in the study and followed up; 38 started treatment with SGLT2i, while the remaining 40 continued their previous antidiabetic therapy. All patients underwent conventional, TDI and strain echocardiography in an ambulatory setting, at the beginning and after 3 months of therapy with SGLT2i | ||
| 520 | |a RESULTS: After 3 months of therapy with SGLT2i, echocardiographic parameters assessing both left and right ventricular dimensions and function were found as significantly improved in patients switching to SGLT2i than control group: LVEF (45 ± 9% vs. 40 ± 8%, p < 0.001), LVEDD (54 ± 6.5 vs. 56 ± 6.5 mm, p < 0.01), GLS (-13 ± 4% vs. -10 ± 3%, p < 0.001), TAPSE (21 ± 3 vs. 19 ± 3 mm, p < 0.001), RV S' (12.9 ± 2.5 vs 11.0 ± 1.9 cm/sec, p < 0.001) and PAsP (24 ± 8 vs. 31 ± 9 mmHg, p < 0.001). Also mitral (1.0 ± 0.5 vs. 1.3 ± 0.5, p < 0.01) and tricuspid regurgitation (1.0 ± 0.5 vs. 1.3 ± 0.5, p < 0.01) improved after SGLT2i therapy. Changes were not statistically significant in patients not treated with SGLT2i (p n.s. in all cases) | ||
| 520 | |a CONCLUSIONS: In a real-world scenario, treatment with SGLT2i in patients with CHF and diabetes is associated with an improvement in both left and right ventricular function assessed at echocardiography. These data may explain potential anti-remodelling effects of gliflozins | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PAsP | |
| 650 | 4 | |a SGLT2 inhibitors | |
| 650 | 4 | |a TAPSE | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a gliflozins | |
| 650 | 4 | |a left ventricular function | |
| 650 | 4 | |a right ventricular function | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 700 | 1 | |a Mazzeo, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Fortunato, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Paradiso, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Furore, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Fanizzi, Angela I |e verfasserin |4 aut | |
| 700 | 1 | |a Tricarico, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Pastore, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Alfieri, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Brunetti, Natale D |e verfasserin |4 aut | |
| 700 | 1 | |a Lamacchia, Olga |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical physiology and functional imaging |d 2002 |g 44(2023), 1 vom: 05. Jan., Seite 112-117 |w (DE-627)NLM118795546 |x 1475-097X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:1 |g day:05 |g month:01 |g pages:112-117 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cpf.12857 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 1 |b 05 |c 01 |h 112-117 | ||